Replay available

Solana Company (HSDT) Q1 2024 Earnings Call

Solana Company (NASDAQ: HSDT) Q1 2024 earnings conference call, held 2024-05-13. Replay captured from the company's public earnings webcast.

Mon, May 13, 2024 at 4:30 PMendedReplay
Solana Company (HSDT) Q1 2024 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Michelle Dilski

Investor Relations, Insight Communications

Dane Andrews

President and Chief Executive Officer

Jeff Mathieson

Chief Financial Officer

Nicholas Sherwood

Analyst, Maxim Group

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Helios Medical Technologies first quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised today's conference is being recorded. I would like to have the conference review speaker today, Michelle Bilski, with Insight Communications. Please go ahead. Thank you, Kevin. Welcome to the first quarter 2024 earnings conference call for Helios Medical Technologies. This is Michelle Dilski of Insight Communications, Investor Relations for Helios. With me on today's call are Dane Andrees, Helios Medical's President and Chief Executive Officer, and Jeff Mathieson, Chief Financial Officer. At this time, all participants have been placed in a listen-only mode. Please note that this call is being recorded and access to the webcast can be obtained through the investor section of the Helios website at www.heliosmedical.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements, including statements regarding potential reimbursement pricing, involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the risk factor section of our most recent annual report on Form 10-K. Such factors may be updated from time to time in our other ...

More from Solana Company